Ananda Developments - Addition to Scientific Advisory Board

ANANDA DEVELOPMENTS PLC

("Ananda" or the "Company")

Addition to Scientific Advisory Board

Ananda Developments plc (AQSE: ANA), a life sciences company focused on the research and clinical development of CBD-based therapies for a range of complex inflammatory pain conditions, is pleased to announce that Professor Marie Fallon has agreed to join the Company's Scientific Advisory Board ("SAB") to provide the Company with expert technical advice and guidance. The SAB is Chaired by Professor Clive Page, a non-executive director of Ananda Developments plc and it held its first meeting in Edinburgh in May 2024.

Prof. Fallon is also the lead investigator for Ananda's Phase II study investigating the pain relieving effects of MRX1 in patients with Chemotherapy Induced Peripheral Neuropathy.

Professor Marie Fallon

Marie Fallon (MD FRCP(Glas) FRCP(E) MRCGP DCH DRCOG). Marie is a Professor of Palliative Medicine at the University of Edinburgh and is an Honorary Consultant in Palliative Medicine based at the Edinburgh Cancer Centre.  Marie has played a significant role in research, leading both national and international research studies around pain and cachexia in cancer patients. Marie has led the development of international palliative care guidelines such as ESMO for cancer pain and ASCO for cachexia. 

Marie has been Joint Editor of four editions of the Oxford Textbook of Palliative Medicine which is the reference textbook in the specialty. Prof. Fallon has edited several other books and sits on numerous grant committees, as well as being an editorial board member of the BMJ Supportive and Palliative Care journal. Finally, of note, much of Marie's recent and current research relates to Low and Middle Income Countries (LMICs), where she is seeking to address the issue of poor opioid availability in LMICs.

Ananda CEO, Melissa Sturgess, commented: "We are delighted and honoured to have Professor Fallon join our SAB. She is a Key Opinion Leader in neuropathy and has conducted previous research using cannabinoids. Her contribution to our drug development work is invaluable and her expertise will be instrumental in ensuring the success of our future research and clinical development programmes."

The Purpose of the SAB is to:

1.   Review, advise and validate Ananda's scientific activities;

2.   Provide strategic advice and guidance including identifying potential areas of unmet medical need that would benefit from Ananda's drug candidates;

3.   Provide advice and guidance on clinical trial and protocol development;

4.   Review publications arising from Company projects; and

5.   Provide advice and guidance as the Company moves through the relevant regulatory pathways required to achieve Marketing Authorisation for its drug candidates.

To stay up to date with the latest developments at Ananda, we encourage you to follow our social media channels which are:  

·      Register at our Investor Hub: https://investors.anandadevelopments.com/s/a66906

·      Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=   

·      LinkedIn: https://www.linkedin.com/company/anadevelopments/   

·      Twitter: https://twitter.com/AnandaPlc

·      Investor Meet Company: https://www.investormeetcompany.com/ananda-developments-plc/register-investor

-Ends-

The Directors of the Company accept responsibility for the contents of this announcement.

For more information please contact:

About Ananda Developments

Ananda is an AQSE-listed company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions.

For further information on the Company visit https://anandadevelopments.com/ or sign up at https://investors.anandadevelopments.com/s/a66906.

https://investors.anandadevelopments.com/link/GyV8jr